CLARUS THERAPEUTICS HOLDINGS (CRXT) Forecast, Price Target & Analyst Ratings

NASDAQ:CRXT • US18271L1070

Current stock price

0.099 USD
-0.06 (-36.94%)
At close:
0.101 USD
+0 (+2.02%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CLARUS THERAPEUTICS HOLDINGS (CRXT).

Forecast Snapshot

Consensus Price Target

Price Target
$3.06
+ 2,990.91% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q3 / 2022
EPS Estimate
-$0.22
Revenue Estimate
6.013M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
77.78%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$3.06
Upside
+ 2,990.91%
From current price of $0.10 to mean target of $3.06, Based on 9 analyst forecasts
Low
$3.03
Median
$3.06
High
$3.15

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

9 Wall Street analysts provided a forecast for the next 12 months for CRXT. The average price target is 3.06 USD. This implies a price increase of 2990.91% is expected in the next year compared to the current price of 0.099.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CRXT Current Analyst RatingCRXT Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

CRXT Historical Analyst RatingsCRXT Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
77.78%
CRXT was analyzed by 9 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CRXT.
In the previous month the buy percentage consensus was at a similar level.
CRXT was analyzed by 9 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2022-08-23NeedhamDowngrade Buy -> Hold
2022-08-22Maxim GroupDowngrade Buy -> Hold
2022-05-17NeedhamMaintains Buy
2022-05-17Truist SecuritiesMaintains Buy
2021-10-13Truist SecuritiesInitiate Buy
2021-10-06NeedhamInitiate Buy
2021-09-29Maxim GroupInitiate Buy
2021-09-20Cantor FitzgeraldInitiate Overweight
2021-09-20OppenheimerInitiate Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q3 / 2022
EPS Estimate
-$0.22
Revenue Estimate
6.013M
Revenue Q2Q
40.30%
EPS Q2Q
14.58%
Number of Analysts
6

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2022 - 2026

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2019 2020 2021 2022 2023 2024 2025 2026
Revenue
YoY % growth
CRXT revenue by date.CRXT revenue by date.
6.369M13.957M
119.14%		19.32M
38.43%		33.166M
71.66%		51.784M
56.14%		83.211M
60.69%		136.384M
63.90%
EBITDA
YoY % growth
CRXT ebitda by date.CRXT ebitda by date.
-17.872M-47.159M
-163.87%		-39.707M
15.80%		-49.572M
-24.84%		-44.37M
10.49%		-15.606M
64.83%		-21.062M
-34.96%		-28.994M
-37.66%
EBIT
YoY % growth
CRXT ebit by date.CRXT ebit by date.
-17.876M-47.177M
-163.91%		-39.732M
15.78%		-36.733M
7.55%		-17.684M
51.86%		-4.75M
73.14%		-7.568M
-59.31%		-12.298M
-62.50%
Operating Margin
CRXT operating margin by date.CRXT operating margin by date.
N/A-740.73%-284.67%-190.13%-53.32%-9.17%-9.09%-9.02%
EPS
YoY % growth
CRXT eps by date.CRXT eps by date.
N/AN/AN/A-1.02
87.39%		-0.43
58.19%		-0.13
70.40%		-0.20
-61.08%		-0.33
-64.30%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 22 Q4 / 22
EPS
Q2Q % growth		-0.22
14.58%		-0.16
15.45%
Revenue
Q2Q % growth		6.013M
40.30%		7.271M
59.37%
EBITDA
Q2Q % growth		-11.73M
-39.39%		-11.73M
-61.90%
EBIT
Q2Q % growth		-9.773M
-15.89%		-8.414M
-15.74%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CRXT Yearly Revenue VS EstimatesCRXT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
CRXT Yearly EPS VS EstimatesCRXT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
25.66%
EPS Next 5 Year
14.39%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
53.57%
Revenue Next 5 Year
57.00%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CLARUS THERAPEUTICS HOLDINGS / CRXT Forecast FAQ

Can you provide the average price target for CLARUS THERAPEUTICS HOLDINGS stock?

9 analysts have analysed CRXT and the average price target is 3.06 USD. This implies a price increase of 2990.91% is expected in the next year compared to the current price of 0.099.

Can you provide the consensus estimates for CLARUS THERAPEUTICS HOLDINGS next earnings?

The consensus EPS estimate for the next earnings of CLARUS THERAPEUTICS HOLDINGS (CRXT) is -0.22 USD and the consensus revenue estimate is 6.01M USD.

How many analysts cover CLARUS THERAPEUTICS HOLDINGS (CRXT) stock?

The number of analysts covering CLARUS THERAPEUTICS HOLDINGS (CRXT) is 9.